Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer.
Wu HJ, Sekine M, Kashima K, Hirai Y, Hatae M, Kobayashi I, Obata K, Enomoto T, Umesaki N, Ushijima K, Tanaka K; Japanese Familial Ovarian Cancer Study Group. Wu HJ, et al. Among authors: hatae m. J Obstet Gynaecol Res. 2005 Oct;31(5):375-83. doi: 10.1111/j.1447-0756.2005.00305.x. J Obstet Gynaecol Res. 2005. PMID: 16176503
Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T, Sekine M, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Nishino K, Haino K, Tanaka K; Japanese Familial Ovarian Cancer Study Group. Amikura T, et al. Among authors: hatae m. Gynecol Oncol. 2006 Feb;100(2):365-71. doi: 10.1016/j.ygyno.2005.09.010. Epub 2005 Dec 9. Gynecol Oncol. 2006. PMID: 16337994
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group. Yoshihara K, et al. Among authors: hatae m. Clin Cancer Res. 2012 Mar 1;18(5):1374-85. doi: 10.1158/1078-0432.CCR-11-2725. Epub 2012 Jan 12. Clin Cancer Res. 2012. PMID: 22241791
Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Inoue I, Tanaka K. Yoshihara K, et al. Among authors: hatae m. Cancer Sci. 2009 Aug;100(8):1421-8. doi: 10.1111/j.1349-7006.2009.01204.x. Epub 2009 May 26. Cancer Sci. 2009. PMID: 19486012 Free PMC article.
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K. Yoshihara K, et al. Among authors: hatae m. PLoS One. 2010 Mar 12;5(3):e9615. doi: 10.1371/journal.pone.0009615. PLoS One. 2010. PMID: 20300634 Free PMC article.
Predicting time to ovarian carcinoma recurrence using protein markers.
Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network; Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Yang JY, et al. Among authors: hatae m. J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. J Clin Invest. 2013. PMID: 23945238 Free PMC article.
Prenatal diagnosis and management of vasa previa: a 6-year review.
Kanda E, Matsuda Y, Kamitomo M, Maeda T, Mihara K, Hatae M. Kanda E, et al. Among authors: hatae m. J Obstet Gynaecol Res. 2011 Oct;37(10):1391-6. doi: 10.1111/j.1447-0756.2011.01544.x. Epub 2011 May 22. J Obstet Gynaecol Res. 2011. PMID: 21599804
[Treatment of platinum-resistant ovarian cancer].
Onishi Y, Nakamura T, Hatae M. Onishi Y, et al. Among authors: hatae m. Nihon Rinsho. 2004 Oct;62 Suppl 10:554-9. Nihon Rinsho. 2004. PMID: 15535307 Review. Japanese. No abstract available.
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T. Ushijima K, et al. Among authors: hatae m. J Clin Oncol. 2007 Jul 1;25(19):2798-803. doi: 10.1200/JCO.2006.08.8344. J Clin Oncol. 2007. PMID: 17602085 Clinical Trial.
86 results